Provided by Tiger Fintech (Singapore) Pte. Ltd.

PDS Biotechnology Corporation

1.08
+0.04003.85%
Post-market: 1.080.00000.00%16:07 EDT
Volume:131.53K
Turnover:141.45K
Market Cap:49.03M
PE:-1.05
High:1.11
Open:1.05
Low:1.03
Close:1.04
Loading ...

BRIEF-Pds Biotech Announces Pds01adc Clinical Data To Be Presented At The American Association For Cancer Research

Reuters
·
08 Apr

PDS Biotech Announces PDS01ADC Clinical Data to Be Presented at the American Association for Cancer Research (Aacr) Annual Meeting 2025

THOMSON REUTERS
·
08 Apr

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

GlobeNewswire
·
08 Apr

PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
28 Mar

Q4 2024 PDS Biotechnology Corp Earnings Call

Thomson Reuters StreetEvents
·
28 Mar

PDS Biotechnology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
28 Mar

PDS Biotechnology Corp : H.c. Wainwright Cuts Target Price to $13 From $21

THOMSON REUTERS
·
27 Mar

PDS Biotechnology Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Mar

PDS Biotechnology FY 2024 GAAP EPS $(1.03) Beats $(1.11) Estimate

Benzinga
·
27 Mar

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

THOMSON REUTERS
·
27 Mar

Press Release: PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Dow Jones
·
27 Mar

PDS Biotechnology Corp expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
25 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts

Insider Monkey
·
23 Mar

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

GlobeNewswire
·
14 Mar

PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Cartesian Therapeutics (RNAC)

TIPRANKS
·
14 Mar

BRIEF-PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer

Reuters
·
13 Mar

PDS Biotechnology Receives FDA Clearance for Versamune MUC1 Trial in Colon Cancer

MT Newswires Live
·
13 Mar

PDS Biotech Announces FDA Clearance of Ind Application for Combination of Versamune® Muc1 and PDS01ADC to Treat Metastatic Colorectal Cancer

THOMSON REUTERS
·
13 Mar